FibroGen’s Roxadustat Rejected By US FDA Panel Due To Safety Concerns, Untested Dosing Strategy

 
• By Sue Sutter
Bumpy road
Roxadustat's bumpy road in the US just got bumpier with a negative adcomm review. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers